Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study
Open Access
- 22 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (1), 233-239
- https://doi.org/10.1038/bjc.2011.511
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 48 references indexed in Scilit:
- Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)Annals Of Oncology, 2011
- Diabetes mellitus, other medical conditions and pancreatic cancer: a case‐control studyDiabetes/Metabolism Research and Reviews, 2010
- Active and Passive Smoking and the Risk of Pancreatic Cancer in the Netherlands Cohort StudyCancer Epidemiology, Biomarkers & Prevention, 2010
- Proton pump inhibitors and risk of gastric cancer: a population-based cohort studyBritish Journal of Cancer, 2009
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UKGut, 2006
- Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trialsBritish Journal of Cancer, 2006
- Association Between Nonsteroidal Anti-Inflammatory Drug Use and the Incidence of Pancreatic CancerJNCI Journal of the National Cancer Institute, 2002
- Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.Gut, 1994
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991